In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Inhibikase Therapeutics (IKT – Research Report), with a price target of $27.00. The company’s shares opened today at $2.45.
According to TipRanks, White is an analyst with an average return of -16.6% and a 26.69% success rate. White covers the Healthcare sector, focusing on stocks such as Karyopharm Therapeutics, Inozyme Pharma, and Inhibikase Therapeutics.
Inhibikase Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $27.00.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $6.95 and a one-year low of $2.30. Currently, Inhibikase Therapeutics has an average volume of 22.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Inhibikase Therapeutics Inc is a clinical stage pharmaceutical company developing therapeutics for Parkinson’s Diseases and related disorders inside and outside the brain. Its pipeline product, IkT-148009, targets underlying disease mechanisms to reverse the course of Parkinson’s disease and the GI complications of Parkinson’s disease.
Read More on IKT:
- Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
- Inhibikase Therapeutics regains Nasdaq compliance
- Inhibikase target adjusted to $27 from $5 for split at H.C. Wainwright
- Inhibikase Therapeutics announces 1-for-6 reverse stock split
- Inhibikase Therapeutics provides update on leukemia studies
